CLVLY Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 июнь 2024 @ 22:28):
Our systems believe the stock currently is overvalued by -0.10% compare to its pairs and should correct downwards.

Stats
Объем за сегодня	2 200
Средний объем	1 903
Рыночная капитализация	491.52M
EPS	$0.220 ( Q2 \| 2023-12-31 )
Дата следующего отчета о доходах	( $0 ) 2024-08-26
Last Dividend	$0.0320 ( 2023-09-07 )
Next Dividend	$0 ( N/A )
P/E	25.82 (Sector) 0 (Industry) 0
ATR14	$0 (0.00%)

ACUT 16.78%

AIMD -3.89%

AKABY 0.00%

AOBI 0.00%

ARNI 417.24%

BETRF 0.00%

BRAXF 7.14%

BVNRY -7.81%

CLVLY -2.39%

COEP 1.05%

CPMV 0.00%

CRXM 0.00%

CSLLY 0.20%

ERGO 0.00%

GSTC 0.00%

IPCIF 0.00%

LVCLY 0.00%

MLCT 2.63%

NPTX 0.00%

NUGX 0.00%

OBMP -37.10%

OCEL -0.27%

ODTC 0.00%

OTLC 6.45%

PFND 0.00%

PROT 0.00%

PVCT 1.11%

QSAM -99.95%

RGBP 10.45%

RGBPP 0.00%

RSPI 8.11%

SIGY 0.00%

SILO 1.01%

SKYE 10.33%

SNNAQ 0.00%

SPHRY 0.00%

UCBJY 0.39%

USRM 0.00%

VGLS 100.00%

VICP 59.29%

WXXWY -1.02%

Корреляция (AI algo v.1.1b): Overvalued: -0.10% $9.81 paired level. (Алгоритм отслеживает изменения наиболее коррелирующих акций в режиме реального времени и дает мгновенное обновление)

Clinuvel Pharmaceuticals Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Clinuvel Pharmaceuticals Финансовые показатели

Annual	2023
Выручка:	$78.32M
Валовая прибыль:	$50.59M (64.59 %)
EPS:	$0.620

FY	2023
Выручка:	$78.32M
Валовая прибыль:	$50.59M (64.59 %)
EPS:	$0.620

FY	2022
Выручка:	$65.72M
Валовая прибыль:	$46.62M (70.93 %)
EPS:	$0.420

FY	2021
Выручка:	$47.98M
Валовая прибыль:	$43.26M (90.16 %)
EPS:	$0.502

Financial Reports:

No articles found.

Clinuvel Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.0270 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.0320 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Clinuvel Pharmaceuticals Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 7.45 - Increase likely (48.95%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0140	2018-09-20
Last Dividend	$0.0320	2023-09-07
Next Dividend	$0	N/A
Payout Date	2023-10-02
Next Payout Date	N/A
# dividends	6	--
Total Paid Out	$0.126	--
Avg. Dividend % Per Year	0.00%	--
Score	3.23	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	7.45
Div. Directional Score	8.90	--

Next Divdend (Est)
(2025-06-30)

$0.0374 Estimate 3.07 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.23

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
07 Sep 2023	$0.0320	30 Aug 2023	08 Sep 2023	02 Oct 2023
09 Sep 2022	$0.0270	02 Sep 2022	12 Sep 2022	03 Oct 2022
03 Sep 2021	$0.0180	01 Sep 2021	06 Sep 2021	27 Sep 2021
04 Sep 2020	$0.0180	30 Nov -0001	30 Nov -0001	30 Nov -0001
06 Sep 2019	$0.0170	30 Nov -0001	30 Nov -0001	30 Nov -0001
20 Sep 2018	$0.0140	30 Nov -0001	30 Nov -0001	30 Nov -0001

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
ORBN	Ex Dividend Junior	2023-09-29	Quarterly	0.00%
BLSFY	Ex Dividend Knight	2023-09-11	Semi-Annually	0.00%
JTEKF	Ex Dividend Junior	2023-09-28	Annually	0.00%
WDFN	Ex Dividend Junior	2023-08-10	Quarterly	0.00%
FIZN	Ex Dividend Junior	2023-08-14	Quarterly	0.00%
SATLF	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
CNBZ	Ex Dividend Junior	2023-07-26	Semi-Annually	0.00%
MCRAB	Ex Dividend Knight	2023-09-20	Quarterly	0.00%
AMNF	Ex Dividend King	2023-07-06	Quarterly	0.00%
HLAN	Ex Dividend Knight	2023-09-22	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.371	1.500	2.58	3.86	[0 - 0.5]
returnOnAssetsTTM	0.142	1.200	5.25	6.30	[0 - 0.3]
returnOnEquityTTM	0.176	1.500	9.16	10.00	[0.1 - 1]
payoutRatioTTM	0.0819	-1.000	9.18	-9.18	[0 - 1]
currentRatioTTM	6.86	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	6.38	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.321	1.500	3.77	5.66	[0.2 - 2]
debtRatioTTM	0.00505	-1.500	9.92	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.843	2.00	9.72	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.725	2.00	9.64	10.00	[0 - 20]
debtEquityRatioTTM	0.00598	-1.500	9.98	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.621	1.000	2.99	2.99	[0.2 - 0.8]
operatingProfitMarginTTM	0.483	1.000	2.33	2.33	[0.1 - 0.6]
cashFlowToDebtRatioTTM	39.55	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.384	0.800	-0.775	-0.620	[0.5 - 2]
Total Score				10.36

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	24.46	1.000	7.63	0	[1 - 100]
returnOnEquityTTM	0.176	2.50	9.46	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.725	2.00	9.76	10.00	[0 - 30]
dividendYielPercentageTTM	0.218	1.500	4.56	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.843	2.00	9.72	10.00	[0 - 30]
payoutRatioTTM	0.0819	1.500	9.18	-9.18	[0 - 1]
pegRatioTTM	0.602	1.500	9.32	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.520	1.000	10.00	0	[0.1 - 0.5]
Total Score				7.45

Clinuvel Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.